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Abstract
GNAQ mutations at codon 209 have been recently identified in approximately 50% of uveal melanomas (UM) and are
reported to be oncogenic through activating the MAPK/Erk1/2 pathway. Protein kinase C (PKC) is a component of signaling
from GNAQ to Erk1/2. Inhibition of PKC might regulate GNAQ mutation-induced Erk1/2 activation, resulting in growth
inhibition of UM cells carrying GNAQ mutations. UM cells carrying wild type or mutant GNAQ were treated with the PKC
inhibitor enzastaurin. Effects on proliferation, apoptosis, and signaling events were evaluated. Enzastaurin downregulated
the expression of several PKC isoforms including PKCbII PKCh, PKCe and/or their phosphorylation in GNAQ mutated cells.
Downregulation of these PKC isoforms in GNAQ mutated cells by shRNA resulted in reduced viability. Enzastaurin exhibited
greater antiproliferative effect on GNAQ mutant cells than wild type cells through induction of G1 arrest and apoptosis.
Enzastaurin-induced G1 arrest was associated with inhibition of Erk1/2 phosphorylation, downregulation of cyclin D1, and
accumulation of cyclin dependent kinase inhibitor p27
Kip1. Furthermore, enzastaurin reduced the expression of anti-
apoptotic Bcl-2 and survivin in GNAQ mutant cells. Inhibition of Erk1/2 phosphorylation with a MEK specific inhibitor
enhanced the sensitivity of GNAQ wild type cells to enzastaurin, accompanied by p27
Kip1 accumulation and/or inhibition of
enzastaurin-induced survivin and Bcl-2 upregulation. PKC inhibitors such as enzastaurin have activity against UM cells
carrying GNAQ mutations through inhibition of the PKC/Erk1/2 pathway and induction of G1 arrest and apoptosis. Inhibition
of the PKC pathway provides a basis for clinical investigation in patients with UM.
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Introduction
Ocular melanomas represent approximately 5% of all melano-
mas, with a majority of these being uveal in origin [1]. Uveal
melanoma (UM) is the most common primary intraocular
malignant tumor in adults, with an annual incidence of seven
cases per million [2]. Approximately 50% of UM patients develop
metastatic melanoma to the liver within 15 years of initial
diagnosis. With distant metastases, there currently is no effective
treatment modality. The median survival for UM patients with
metastasis is less than six months [1].
The etiology of UM has not been fully understood. Although
uveal and cutaneous melanomas arise from the same cell type,
they have distinct genetic alterations. Genetic mutations in the
TP53, BRAF, RAS, CDKN2 and PTEN genes are common in
cutaneous melanoma but rare in UM [3]. Drugs commonly used
to treat cutaneous melanoma seldom produce durable responses in
UM patients. The preponderance of liver metastases in uveal
melanoma patients has focused therapeutic effort in local control
of metastatic disease for palliation [4,5]. Recently, somatic muta-
tions in the GNAQ gene have been identified in about 50% of UM
and 83% blue naevi [6,7]. GNAQ mutations occurring at codon
209 of the RAS-like domain result in constitutive activation of the
MAPK/Erk1/2 pathway in melanocytes and confer dominantly
acting oncogenic functions to GNAQ [7]. The GNAQ gene
encodes for the a subunit of q class of heterotrimeric GTP binding
protein (Gq) that mediates signals from G-protein-coupled receptors
(GPCRs) and stimulates all four isoforms of b phospholipase C
(PLCb) [8]. PLCb enzymes catalyze the hydrolysis of phosphatidy-
linositol biphosphate, to release inositol trisphosphate and diacyl-
glycerol (DAG) that function as second messengers and propagate
and amplify the Ga-mediated signal through stimulation of pro-
tein kinase C (PKC). It has been hypothesized that signaling
from GNAQ to MAPK/Erk1/2 is transmitted through DAG/
PKC [9].
The PKC family is a widely expressed group of serine/
threonine kinases comprising at least twelve isoforms [10]. PKCs
are involved in key cellular processes including cell proliferation,
apoptosis, and differentiation. Increased PKC expression and
activity have been demonstrated in many cancers [10–13]. PKCs
may play important roles in tumor formation and progression,
invasiveness of cancer cells, and chemoresistance [13–15]. The
mechanisms by which PKCs contribute to tumorigenesis, however,
are not fully understood [16].
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inhibitor of PKCb at low concentrations (IC50, 6 nmol/L) [17]
and inhibits other PKC isoenzymes at higher concentrations [18].
In addition, enzastaurin targets the phosphatidylinositol 3-kinase/
AKT pathway, and inhibits phosphorylation of GSK3b (Ser9) and
ribosomal protein S6 (Ser240/244) [18]. Although enzastaurin
was initially developed as an antiangiogenic agent, it also has
direct proapoptotic and antiproliferative activities on various
human cancer cells [18–25]. Therefore, enzastaurin may exhibit
antitumor activity through multiple mechanisms affecting both
tumor angiogenesis and apoptosis.
Given the importance of PKC in tumorigenesis [10,15] and
potentially in GNAQ mutation-induced MAPK activation [7], we
hypothesized that PKC may provide new opportunities for
therapeutic intervention of UM carrying GNAQ mutations. In
the present study, we tested this hypothesis by examining the
response of UM cells with wild type or mutant GNAQ toward the
antiproliferative and proapoptotic action of enzastaurin and
characterized the underlying signaling and molecular mechanisms.
Results
UM cells harboring GNAQ mutations experience
increased inhibition of cell viability by enzastaurin
A panel of eleven UM cell lines was used to evaluate the
antiproliferative effect of enzastaurin (Figure 1A). DNA sequenc-
ing confirmed that cell lines Omm1.3 (accession number
JN184781), Mel202 (accession number JN184779) and 92.1
(accession number JN184780) carry a mutation at codon 209 of
GNAQ while the remaining cell lines are wild type for GNAQ. No
mutations were found at codon 183 of GNAQ and at codons 209
and 183 of GNA11 in all these cell lines. Cell lines Ocm1 and
Ocm3 have been reported to harbor BRAF V600E mutation [26].
While a dose-dependent decrease in viability was seen in all eleven
UM cell lines tested, greater inhibition was noted in the three cell
lines harboring GNAQ mutations (Figure 1B). The IC50 of
enzastaurin was 2–4 mM for the cell lines with mutations,
compared to 8 mM or greater for the wild type cell lines.
We next looked for evidence that the response of UM cells to
enzastaurin is related to mutational status using statistical analyses.
The statistical model results indicate that the effect of enzastaurin
upon viability depends upon both the mutational status and
enzastaurin concentration (interaction p-value=0.0001). On
average, viability was reduced less in the wild type cell lines, even
at high concentrations of enzastaurin (Fig. S1). For wild type cell
lines, viability decreased by approximately 7% (95% CI: 6.6% to
8.2%) for each unit increase in enzastaurin concentration. In
mutated cell lines, there was an estimated decrease of 21% (95%
CI: 19.8% to 22.6%) in viability for each unit increase in
enzastaurin concentration (Table S1). Based upon the estimated
equations, the EC50 values are 9.15 mM and 2.85 mM for wild
type and mutated cell lines, respectively. There is little evidence for
differences in response in enzastaurin concentrations of 1 mMo r
less. At concentrations of 2 mM or above, there was a statistically
significant reduction in the viability of mutated cell lines compared
with wild type.
Enzastaurin induces cell cycle arrest and apoptosis in UM
cells
To better understand the differential responses of UM cells
based on GNAQ mutational status, we investigated cell cycle
progression alterations with drug exposure. Enzastaurin treatment
for 48 hours significantly increased the G1 population while
decreasing the S population in all three cell lines harboring GNAQ
mutations (Figure 2). In agreement with these findings, enzastaurin
significantly decreased BrdU incorporation in mutant cell lines
(Figure 3). These results suggest that enzastaurin induced G1
arrest in the cell lines harboring mutations. In comparison, the G1
population of the wild type cell lines was either unaltered (C918
and Ocm3) or decreased by enzastaurin (Ocm1 and Mel285). A
significant increase in the G2/M population was observed in
Ocm1 and Mel285 cells. A mild increase in the S population and a
significant increase in BrdU uptake were observed in Ocm3 cells
treated with 5 and 10 mM enzastaurin (Figures 2 and 3).
As enzastaurin is known to induce apoptosis in many types of
cancer cells [18–25], we next examined whether enzastaurin
induced apoptosis of UM cells using Annexin V-FITC staining.
Treatment with 4 mM enzastaurin for 72 hours induced a slight
increase (10.4%) in apoptosis in mutant cell line 92.1 but not in the
wild type cell line C918 (Figure 4, left panel). Because enzastaurin
Figure 1. UM cells that harbor GNAQ mutations are more sensitive to the anitproliferative activity of enzastaurin. A, UM cell lines
used in the present study. B, enzastaurin exhibited greater antiproliferative effects on UM cell lines carrying GNAQ mutations (MT) than those with
wild type GNAQ (WT). Cells were treated with varying amount of enzastaurin for 72 hours and subjected to MTS assay. Results are presented as mean
6 SD of percent viability from three independent experiments.
doi:10.1371/journal.pone.0029622.g001
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concentrations would increase its apoptotic effects. In the presence
of 1% serum, treatment with 5 mM enzastaurin for 72 hours
induced substantial apoptosis in the cell lines Mel202, 92.1 and
Omm1.3 harboring GNAQ mutations, and in the wild type cell
lines Ocm1 (harboring a BRAF mutation), but failed to do so in
cell line C918 which is wild type for GNAQ (Figure 4A, right
panel). An increase in cleaved caspase-3 fragments was also
observed in enzastaurin-treated Mel202, 92.1 and Omm1.3
mutant cells and Ocm1 wild type cells, but not C918 cells
(Figure 4B). These findings suggest that UM cells carrying GNAQ
mutations and some GNAQ wild type/BRAF mutant cells are
more sensitive to the apoptotic activity of enzastaurin and that
enzastaurin exerted increased antiproliferative effect on GNAQ
mutant UM cells through induction of G1 arrest and apoptosis.
Enzastaurin increases p27
Kip1 expression and decreases
the expression of cyclin D1 in GNAQ mutant UM cells. To
understand the molecular mechanisms underlying enzastaurin-
induced G1 arrest in GNAQ mutant UM cells, we investigated the
enzastaurin response of cell cycle regulatory molecules, including
cyclin D1 and p27
Kip1 that regulate cell cycle progression through
G1 phase [28]. In all three GNAQ mutant UM cell lines treated
with enzastaurin, the expression of p27
Kip1 was markedly in-
creased, while the expression of cylin D1 was reduced (Figure 5A).
Enzastaurin had minimal effect on p27 and cyclin D1 expression
in GNAQ wild type cells. These findings are in line with
enzastaurin-induced G1 arrest occurring only in GNAQ mutant
lines, and suggest that cyclin D1 and p27 dysregulation are
molecular mechanisms for enzastaurin-induced G1 arrest.
Enzastaurin decreases the expression of Bcl-2 and
survivin in GNAQ mutant UM cells. We next examined the
effect of enzastaurin on the expression of antiapoptotic (survivin,
Bcl-2, Bcl-xL, XIAP, Mcl-1, and ARC) and proapoptotic (p53 and
Bim) proteins. Enzastaurin significantly inhibited survivin
expression in all three cell lines with GNAQ mutations and in
GNAQ wild type cell line Mel285 (Figure 5B). It is noteworthy
that the mutant cell lines expressed significantly higher levels of
Bcl-2 compared with wild type cell lines (Figure 5B and
unpublished data). Enzasaturin decreased Bcl-2 expression in the
mutant cell lines and appeared to slightly increase (C918 and
Ocm1 cells) or have little effect (Mel285) on its expression in the
wild type cells. The expression of p53, Bcl-xL, XIAP, Mcl-1, Bim
Figure 2. Enzastaurin induced G1 arrest in UM cells carrying GNAQ mutations. A, cells were treated with enzastaurin for 48 hours, stained
with PI and subjected to FACS analysis of cell cycle distribution. B, percentages of G1, S, G2/M, and sub-G1 populations were estimated using
software ModFit. Mean percentages of each population from 3–5 independent experiments are presented as bar graphs. * P,0.05, versus control; #
P,0.01, versus control. WT=GNAQ wild type; MT=GNAQ mutation.
doi:10.1371/journal.pone.0029622.g002
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wild type or mutant cell lines (Figure S2).
Enzastaurin decreases Erk1/2 phosphorylation in UM
cells harboring GNAQ mutations. We next investigated
whether enzasaturin affected Akt and Erk1/2 activation that are
critical for UM development. Erk1/2 activation has been reported
to be induced by mutant GNAQ and has been found in UM
independent of GNAQ, BRAF and RAS mutational status
[7,27,34]. Akt but not Erk1/2 phosphorylation has been
reported to be inhibited by enzastaurin in several types of
cancer cells [18,22,24,25,35–39]. Interestingly, Erk1/2 phos-
phorylation was significantly suppressed in all three GNAQ
mutant cell lines by enzastaurin but only in one GNAQ wild type
cell line (Mel285) (Figure 6). In contrast, Akt (Ser473) phos-
phorylation was affected by enzastaurin only in GNAQ wild type
cell line Mel285. Total Akt and Erk1/2 levels were not
significantly affected by enzastaurin in the wild type as well as
the mutant cell lines. These findings suggest that enzastaurin may
exert its antiproliferative action on GNAQ mutant cells in part
through targeting the MAPK pathway. Enzastaurin inhibited
GSK3b phosphorylation and induced b-catenin expression in both
wild type and mutant cell lines (Figure S3), consistent with its
known mechanism of activity.
Inhibition of Erk1/2 phosphorylation increases the
antiproliferation effects of enzastaurin on wild type UM
cells. To better understand the role of the MAPK pathway in
the response of UM cells to enzastaurin, we treated C918 and
Ocm1 cells with enzastaurin in the presence of 20 mM U0126, an
MEK specific inhibitor. As expected, U0126 inhibited Erk1/2
phosphorylation, but had little effect on total Erk1/2 (Figure 7A).
U0126 reduced both basal and enzastaurin-induced expression of
survivin in C918 and Ocm1 cells (Figure 7A). U0126 reduced
basal expression of Bcl-2 in Ocm1 cells and enzastaurin-induced
expression of Bcl-2 in C918 and Ocm1 cells. Furthermore, U0126
increased p27
Kip1 expression in Ocm1 and C918 cells which was
further augmented in the presence of enzastaurin in Ocm1 cells
but not in C918 cells (Figure 7A). The expression of cyclin D1 was
repressed in Ocm1 cells treated with U0126 alone or in
combination with enzastaurin (Figure 7A). Interestingly, U0126
Figure 4. Enzastaurin induced apoptosis in UM cells expressing mutant GNAQ. A, cells were treated with 4 and 5 mM enzastaurin in the
presence of 1% and 10% FBS for 72 hours, respectively. Apoptotic cells were detected using Annexin V-FITC staining and FACS analysis. B,
immunoblot analysis of cleaved casapase-3 in cells treated with 5 mM enzastaurin in the presence of 1% FBS for 48 hours. WT=GNAQ wild type;
MT=GNAQ mutation.
doi:10.1371/journal.pone.0029622.g004
Figure 3. Effect of enzastaurin on BrdU incorporation. UM cells
were treated with enzastaurin at indicated concentrations for 40 h and
then labeled with BrdU for additional 6–8 hours. BrdU incorporation
was presented as % of untreated control. Mean 6 SD of 3 independent
experiments are shown. * P,0.05, versus control; # P,0.01, versus
control. WT=GNAQ wild type; MT=GNAQ mutation.
doi:10.1371/journal.pone.0029622.g003
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resulting in an IC50 comparable to that found in cells harboring
GNAQ mutations (Figure 7B). U0126 also enhanced the
antiproliferation effects of enzastaurin on Ocm1 cells at lower
concentrations (1–4 mM versus 6–10 mM) (Figure 7B). Similar
effect on proliferation was also observed in enzastaurin-treated
C918 and Ocm1 cells with another MEK inhibitor AZD6244
(Figure S4). As UM cells harboring GNAQ mutations concerned,
only Mel202 cells showed increased sensitivity to enzastaurin in
the presence of U0126 (Figure 7B). U0126 and AZD6244 alone
showed varying inhibitory effects on proliferation of GNAQ wild
type and mutant UM cell lines, with AZD6244 having greater
inhibitory effects (Figure S5).
Enzastaurin affects the expression and phosphorylation
of PKCb, PKCe and PKCh in UM cells harboring GNAQ
mutations. In order to determine whether the antiproliferative
action of enzastaurin is mediated via inhibition of PKC, we
investigated the effect of enzastaurin on the expression and
activation of PKC isoforms. Immunoblotting revealed varying
expression of PKC isoforms in UM cell lines (Figure 8A). UM cell
treatment with enzastaurin in the absence of serum for 6 hours
inhibited the expression of PKCh and PKCe in Mel202 and 92.1
cells, but not in C918 cells (Figure 8A). By contrast, enzastaurin
had little effect on PKCa, PKCb, and PKCd expression.
Furthermore, enzastaurin inhibited PKCe phosphorylation
dramatically in Mel202 and 92.1, but not C918 cells, whereas
PKCh phosphorylation was partially inhibited in all (Figure 8A).
It has been reported that enzastaurin downregulates the
expression of PKC isoforms [24,29], and we therefore examined
the effect of enzastaurin on the expression of PKCbII, PKCe, and
phospho-PKCb in UM cells after prolonged (72 hours) treatment
and in the presence of serum (Figure 8B). As described above,
enzastaurin decreased the expression of PKCe in 92.1 and Mel202
cells but not in C918 and Mel285 cells. Enzastaurin decreased
PKCe expression in Ocm1 cells but not in Omm1.3 cells,
indicating its effect on PKCe expression is independent of GNAQ
status. Similarly, varying levels of PKCbII expression were seen
among these UM cell lines. While enzastaurin did not significantly
alter PKCbII expression in C918 and Ocm1 cells, it did decrease
PKCbII expression in Omm1.3, Mel202, and 92.1 cells harboring
GNAQ mutations. Enzastaurin decreased PKCb phosphorylation
in Ocm1, Mel285, Omm1.3, Mel202, and 92.1 cells, with the
Figure 5. Effects of enzastaurin on the expression of cell cycle (A) and apoptosis (B) regulatory proteins in GNAQ wild type and
mutant UM cells. Cells were treated with enzastaurin for72 hours andanalyzedby immunoblot analysis. WT=GNAQwild type; MT=GNAQmutation.
doi:10.1371/journal.pone.0029622.g005
Figure 6. Effects of enzastaurin on Akt and Erk1/2 activation in UM cells. Cells were treated with enzastaurin for 72 hours and analyzed for
the expression of Akt and Erk1/2 and their phosphorylation by immunoblot analysis. WT=GNAQ wild type; MT=GNAQ mutation.
doi:10.1371/journal.pone.0029622.g006
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PKCb phosphorylation was slightly increased in C918 cells after
treatment with 10 mM enzastaurin.
PKCh, PKCb, and PKCe are functionally important for
UM cells harboring GNAQ mutations. As enzastaurin
inhibited the expression and/or phosphorylation of PKCb,
PKCe, and PKCh in UM cells harboring GNAQ mutations, we
investigated the functional importance of these PKC isoforms by
shRNA-mediated downregulation. Infection of C918 and Mel202
cells with lentivirus expressing shRNA of PKCb, PKCe or PKCh
reduced the protein levels of corresponding isoforms in these cells
(Figure 8C). It is noteworthy that in both C918 and Mel202 cells
expressing PKCb shRNA, PKCe protein levels were also reduced.
A reduction in PKCh protein abundance was also detected in
PKCb shRNA expressing Mel202 cells. In C918 and Mel202 cells
expressing PKCe, PKCb expression was downregulated as well. In
Mel202 cells expressing PKCh, the expression of PKCb and
PKCe was modestly increased. Notably, expression of PKCb,
PKCh or PKCe shRNA significantly decreased viability of Mel202
and Omm1.3 cells (Figure 8D). A reduction in viability was also
seen in C918 cells expressing shRNA of PKCb, PKCe or PKCh
and in Mel285 cells expressing PKCb or PKCh, but to less extent
compared to GNAQ mutated cells. Significant viability reduction
was seen with second shRNA for each of these PKC isoforms in
Mel202 cells but not in C918 cells (Figure S6). These findings
suggest that PKCh PKCb, and PKCe may functionally be more
important for UM cells harboring mutated than those with wild
type GNAQ. In supporting this notion, we were able to establish
C918 but not Mel202 stable cell line expressing PKCh shRNA
(data not shown). Altogether our findings support the notion that
enzastaurin may exert anti-proliferative action via the inhibition of
these PKC isoforms.
Discussion
GNAQ mutations at codon 209 have been recently found in
nearly 50% of UM patients [6,7]. These mutations can lead to
activation of a number of cell signaling pathways. In the present
study, we demonstrate for the first time that UM cell lines
harboring GNAQ mutations are more sensitive to the antiprolif-
erative effects of the PKC inhibitor enzastaurin than those
possessing wild type GNAQ. Enzastaurin inhibits proliferation of
mutant UM cells through induction of G1 cell cycle arrest and
apoptosis. We have further characterized signaling and molecular
mechanisms underlying differential responses of GNAQ wild type
and mutant cells to enzastaurin.
The PI3K/Akt and MAPK pathways are frequently activated in
malignant tumors [30–32]. Erk1/2 activation is commonly found
in UM, independent of GNAQ, RAS, and BRAF mutational
status [27,33,34], and are crucial for UM development [34].
GNAQ mutations have been reported to be oncogenic through
activating the Erk1/2 pathway in UM cells [7]. In the current
study, we show that enzastaurin reduced Erk1/2 phosphrylation in
all three GNAQ mutant UM cell lines and in one wild type cell
line (Mel285). Erk1/2 phosphorylation has been shown to be
unaltered or increased by enzastaurin in several cancer types
[22,24,35–39], whereas Akt phosphorylation has been reported to
be downregulated by enzastaurin, likely through an indirect
Figure 7. Effect of MEK inhibition on the antiproliferative action of enzastaurin. A, expression of Erk1/2, phospho-Erk1/2, survivin, Bcl-2,
cyclin D1, and p27
Kip1 in C918 and Ocm1 cells treated with enzastaurin in the absence or presence of U0126 (20 mM) for 72 hours. B, effect of U0126
on the antiproliferative activity of enzastaurin. Assay was performed as described in Figure 1 in the absence or presence of 10 mM U0126. Results are
presented as mean 6 SD of percent viability from 4–5 independent experiments. * P,0.05, versus DMSO at the same dose of enzastaurin.
doi:10.1371/journal.pone.0029622.g007
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However, enzastaurin has also been reported to have little effect
on Akt phosphorylation in glioma cells [36]. In the UM cells
studied here, Akt phosphorylation was only affected in Mel285
cells by enzastaurin. Interestingly, although both Akt and Erk1/2
phosphorylation were decreased by enzastaurin, Mel285 cells, like
other GNAQ wild type cells, were less sensitive to enzastaurin in
comparison to GNAQ mutated cells where only Erk1/2
phosphorylation was affected. In agreement with sensitivity to
enzastaurin, inhibition of Erk1/2 phosphorylation was accompa-
nied by increased p27
Kip1 accumulation and decreased expression
of cyclin D1, Bcl-2 and survivin in GNAQ mutant cells whereas
only survivin was downregulated in Mel285 cells. Furthermore,
inhibition of Erk1/2 phosphorylation by MEK1/2 inhibitors
increased sensitivity of GNAQ wild type cells to enzastaurin and
was associated with similar alterations in the expression of p27
Kip1,
cyclin D1, Bcl-2 and/or survivin to GNAQ mutant cells treated
with enzastaurin. Our findings suggest that the suppression of
Erk1/2 phosphorylation may be the major contributor to the
increased sensitivity of GNAQ mutant UM cells to the anti-
proliferative action of enzastaurin through altering the expression
of p27, ccyclin D1, Bcl-2 and survivn. These observations further
support the oncogenic role for GNAQ mutations via activation of
MAPK [7].
The signaling pathways downstream of GNAQ are multifold
and include activation of the PKC family members [8]. Our results
indicate that UM cell lines have varying expression and
phosphorylation patterns of PKC isoforms, independent of GNAQ
mutational status. The effects of enzastaurin on the expression and
phosphorylation of PKC isoforms in UM cells are complex.
Additional studies are needed to determine whether GNAQ
mutational status influences the effects of enzastaurin on various
PKC isoforms and the potential therapeutic ramifications of these
effects. Nonetheless, some PKC isoforms were downregulated by
enzastaurin in UM cell carrying GNAQ mutations. In particular,
the expression and phosphorylation of PKCh, PKCe, and PKCb
were reduced by enzastaurin in GNAQ mutated cells. Our
functional studies revealed that these PKC isoforms are indeed
more critical for growth of UM cells harboring GNAQ mutations
than those with wild type GNAQ. Together, our findings suggest
that enzastaurin may exert increased antiproliferative action
through inhibiting these PKC isoforms in GNAQ mutated UM
cells. Inhibition of these isoforms may play a role in enzastaurin-
induced inhibition of Erk1/2 phosphorylation, since activation of
PKCe and PKCbII have been shown to trigger several major
signaling pathways including MAPK [40,41]. In addition, the
inhibition of PKCbII by enzastaurin or small interfering RNA
decreased Erk1/2 phosphorylation in metastatic hepatocellular
carcinoma cells [42]. It is noteworthy that although enzastaurin
had little effect in general on the expression and/or phosphory-
lation of PKC isoforms in GNAQ wild type C918 cells, it did
decrease the expression of PKCe and PKCb phosphorylation in
Figure 8. PKCb, PKCe and PKCh are functionally important for UM cells harboring GNAQ mutations. A and B, enzsaurin reduced the
expression and phosphorylation of PKCb, PKCe and PKCh. Cells were treated with enzastaurin for 6 hours in the absence of serum (A) or for 72 hours
in the presence of 10% FBS (B). pPKCe Thr566 was detected using pan p-PKC antibody raised against pPKCf Thr410. Note that the expression of PKCb
was under detectable level of Western blot in Mel285 cells (B). C, knockdown of PKCb, PKCe, and PKCh by shRNA. C918 and Mel202 cells were infected
with lentivurs expressing shRNA for each PKC isoform for 4 days and protein levels of these isoforms were determined by immunoblot blot analysis.
D. Effects of knockdown of PKCb, PKCe, and PKCh on viability of UM cells. Cell viability was determined 4 days after infection with lentivrus expressing
PKC shRNA using MTS assay. Results are presented as mean 6 SD of percent viability from 3 independent experiments. *P,0.05 and # P,0.01,
versus cells expressing GFP control shRNA.
doi:10.1371/journal.pone.0029622.g008
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did not significantly alter Erk1/2 phosphorylation in both cell
lines, suggesting other PKC isoforms and/or PKC independent
mechanisms for Erk1/2 activation in Ocm1 cells. Complicating
this interpretation, Ocm1 cells have been shown to carry the
common V600E BRAF mutation that constitutively activates the
MAPK pathway [43,44]. Furthermore, PKCa and PKCd have
been reported to activate Erk1/2 in mouse melanoma [51]. Both
PKCa and PKCd are expressed in Ocm1 cells (unpublished data).
In the present study, we demonstrate that enzastaurin-induced
antiproliferation of UM cells carrying GNAQ mutations is
associated with G1 arrest. Enzastaurin has been shown to have
little effect on cell cycle progression in many types of cancers [25].
Recently, it was reported to induce G1 arrest in non-small cell
lung cancer cells [37]. Enzastaurin-induced G1 arrest in UM cells
is associated with downregulation of the positive cell cycle
regulators cyclin D1 and upregulation of negative cell cycle
regulator p27
Kip1. This recapitulates the Erk1/2 inhibition-
induced G1 arrest by MEK inhibition that is characterized by
decreased expression of cyclin D1 and accumulation of p27
Kip1
[45–47]. This further supports that enzastaurin may induce G1
arrest primarily through the MAPK pathway. Downregulation of
survivin has been shown to be associated with rapamycin-induced
G1 arrest [52] and may also play a role in enzastaurin-induced G1
arrest reported here. However, enzastaurin did not induce G1
arrest in Mel285 cells where survivin expression was suppressed.
This suggests that survivin downregulation alone is not sufficient to
induce G1 arrest and alterations in other G1-S transition
regulatory proteins such as p27 and cyclin D1 are required. G1
arrest can be induced by reduced expression of other cell cycle
regulatory proteins including cylins D3, E and A and CDK4
[52,53]. It remains to be examined whether enzastaurin
downregulates the expression of these proteins. Enzastaurin either
has no effect on cell cycle or increases G2/M population in UM
cell lines with wild type GNAQ. It is intriguing that one of the
GNAQ wild type UM cell lines was found to harbor a BRAF
mutation and the implication of this biology to a PKC inhibitor
such as enzastaurin remains to be investigated.
We have also demonstrated that enzastaurin induces apoptosis
in UM cells carrying GNAQ mutation. Enzastaurin-induced
apoptosis is associated with the downregulation of antiapoptotic
Bcl-2 and survivin, while the expression of other common
apoptosis regulators was not significantly altered. Both MAPK
and Akt pathways have been reported to induce Bcl-2 and survivin
expression [48–50]. As the Akt pathway was minimally affected by
enzastaurin, the downregulation of Bcl-2 and survivin by
enzastaurin may be the result of decreased activation of the
MAPK pathway in cells carrying GNAQ mutations. This is
supported by our findings that MEK inhibition also downregu-
lated the expression of Bcl-2 and/or survivin in the wild type cells.
Interestingly, the expression of survivin but not Bcl-2 was
decreased in Mel285 cells where both Erk1/2 and Akt
phosphorylation was suppressed by enzastaurin. This suggests
that additional signaling pathway(s) may be involved in Bcl-2
expression in these cells. The molecular mechanisms underlying
apoptosis induced by enzastaurin seen in some UM cell lines with
wild type GNAQ remains to be investigated.
In summary, compared with UM cells with wild type GNAQ,
the PKC inhibitor enzastaurin at low micromolar concentrations
exerts significant antiproliferative effect on UM cells carrying
GNAQ mutations through targeting PKC/MAPK pathways with
induction of G1 arrest and apoptosis. Our findings suggest that
enzastaurin and other compounds affecting PKC and related
pathways could be of therapeutic potential for UM.
Materials and Methods
Cell Lines
UM cell lines M619, C918, Mum2B, Mum2C, Ocm1 and
Ocm3 were kindly provided Dr. L. Chin (Dana-Farber Cancer
Institute, Boston, MA). UM cell lines Mel202, 92.1 and Ocm1A
were kindly provided by Dr. J. W. Harbour (Washington
University, St. Louis, MI), Mel285 by Dr. D. Fisher (Massachu-
setts General Hospital, Boston, MA), and Omm1.3 by Dr. B.
Bastian (University of California, San Francisco, CA). It has been
reported by Folberg and colleagues in studies authenticating cell
lines that Ocm1 and Mum2C are from the same patient, and that
M619, C918, and Mum2B are from the same patient [26]. UM
cells were cultured in RPMI 1640 supplemented with 10% FBS,
50 mg/ml penicillin, and 100 mg/ml streptomycin at 37uC and 5%
CO2. In some experiments, in order to analyze the effect of
enzastaurin on PKC isoforms, cells were incubated with or without
enzastaurin in serum-free media.
Cell viability assay
Cells were seeded in 96-well plates at 2610
3 cells per well and
incubated overnight. Cells were then treated with enzastaurin
(provided by Eli Lily and Company, Indianapolis, Indiana),
MEK1/2 inhibitor U0126 (Cell Signaling Technology, Danvers,
MA) or AZD6244 (Selleck Chemicals, Houston, TX) for three
days. Cell viability was determined by MTS proliferation assay
(Promega, Madison, WI) as per manufacturer’s instructions. For
signaling pathway experiments, cells were treated with enzastaurin
in the presence of U0126 (10 mM) or AZD6244 (2 mM).
Cell cycle analysis
Cells were harvested by trypsinization and fixed in cold ethanol.
After treatment with RNase, cells were stained with PI and subjected
to flow cytometry analysis (FACS) to determine cell cycle distribution.
BrdU uptake analysis
Cells were plated in 96-well plates at 4610
3 cells/well in growth
medium and incubated overnight. Cells were treated with 0, 5, and
10 mM enzastaurin for 40 h. BrdU were added to the cells and
allowed the cells to be labeled for 6–8 hours. Cell labeling with
BrdU, fixation and detection were performed using a BrdU Cell
Proliferation Assay kit as guided by the manufacturer (EMD
Chemicals, Gibbstown, NJ). BrdU incorporation was presented as
% of untreated control.
Analysis of apoptosis
Cells were stained with Annexin V-FITC using an Apoptosis
detection kit (BD Biosciences, San Jose, CA) and subjected to flow
cytometry analysis according to the instructions provided by the
manufacturer. Compensation for enzastaurin autofluorescence was
performed.
Immunoblot analysis
Cells were treated in lysis buffer (Cell Signaling) supplemented
with protease inhibitors (Roche, Minneapolis, MN). Equal
amounts of cell lysates were subjected to electrophoresis on SDS
polyacrylamide gels. Proteins were transferred onto nitrocellulose
membranes (Bio-Rad Laboratories, Hercules, CA). The mem-
branes were blocked with 5% nonfat dry milk or BSA, incubated
with primary and second antibodies, and developed by ECL.
Antibodies against PKC isoforms were: PKCh (BD Biosciences
#610090); PKCh Thr538 (Cell Signaling #9377); PKCh/d
Ser643/676 (Cell Signaling #9376); PKCe (BD Biosciences
#610085); pan-phospho-PKC (PKCc Thr514, Cell Signaling
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phosphorylated at a residue homologous to PKCc Thr514); pan-
phospho-PKC (PKCf Thr410, Cell Signaling #2060, recognizing
PKCs a, bI, bII, c, e, h, d, g, and i, when phosphorylated at a
residue homologous to PKCf Thr410); and pan-phospho-PKCbII
Ser660 (Cell Signaling #9371). Antibodies against Akt, phospho-
Akt, Erk1/2, phospho-Erk1/2, cyclin D1, p53, b-catenin, Bcl-2,
Bcl-xL, XIAP, survivin, GSK3b and phospho-GSK3b were
purchased from Cell Signaling Technology. Antibodies against
PKCbII, P27
Kip1, ARC, and BIM were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Actin antibody was
purchased from Sigma-Aldrich (St. Louis, MI). Data shown are
representatives of 2 or more experiments.
Knockdown of PKC isotypes by shRNA
The constructs (pLKO.1-puro) containing shRNA target
sequences for PKCb, PKCe, PKCh or GFP (used as control)
were provided by Dana-Farber Cancer Institute shRNA Core
Facility. Lentivirus was produced by co-transfection of 293T cells
with pLKO.1-puro, pCMVDR8.91 and pMD.G according to the
protocol provided by the facility. Cells were infected with virus for
4 days and cell viability was determined using MTS assay.
DNA sequence data deposition
All new data has been deposited in GenBank (accession
numbers JN184778, JN184779, JN184780 and JN184781).
Statistical Methods
Graphs of the original viability data of UM cell lines suggested a
curvilinear relationship between proliferation and concentration of
enzastaurin. For comparison between GNAQ wild type and
mutated groups, viability data were natural log (base e) trans-
formed for the statistical models to make the concentration-
response relationship more linear. Log-transformed data were fit
using random effects, mixed models, with mutation status, con-
centration of enzastaurin, and their interaction as independent
predictors. Maximum likelihood estimates from the model are
summarized with 95% confidence intervals. Statistical analyses
were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC). For
statistic analysis of changes in viability and cell cycle distributions
of each cell line two-tailed t-test was used.
Supporting Information
Figure S1 Statistical modeling of data from viability
assays. A, the original data after log transformation. For each cell
line, the replicates were averaged and represented as dots. B,
transformed data were averaged across replicates by mutational status.
(TIF)
Figure S2 Immunoblot analysis of apoptosis regulatory
proteins in UM cells with or without enzastaurin
treatment for 72 hours.
(TIF)
Figure S3 Effect of enzastaurin on GSK3b signaling in
UM cells. Cells were treated with enzastaurin for 72 hours in the
presence of 10% FBS. Note that the expression of GSK3b and
pGSK3b Ser9 was under detectable levels of immunoblot in
Omm1.3 cells.
(TIF)
Figure S4 Effect of AZD6244 on the antiproliferative
activity of enzastaurin. Assay was performed as described in
Figure 1 in the absence or presence of 2 mM AZD6244. Results
are presented as mean 6 SD of percent viability from 2–3
independent experiments. * P,0.05, versus DMSO; # P,0.01,
versus DMSO at the same dose of enzastaurin.
(TIF)
Figure S5 Effect of MEK inhibitors on UM cell viability.
A, U0126. B, AZD6244. UM cells were treated with varying
amount of U0126 or AZD6244 for 72 hours and subjected to
MTS assay. Results are presented as mean 6 SD of percent
viability from 2 independent experiments.
(TIF)
Figure S6 Effect of second shRNA for PKCb, PKCe, and
PKCh on C918 and Mel202 cell viability. Experiments
were performed as described in figure 8. Results are
presented as mean 6 SD of percent viability from 3 independent
experiments. # P,0.01 versus cells expressing GFP control shRNA.
(TIF)
Table S1 Viability reduction rate of GNAQ mutant
compared to wild type UM cell lines at various
concentrations of enzastaurin.
(TIF)
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